1. Home
  2. VIGL vs MNOV Comparison

VIGL vs MNOV Comparison

Compare VIGL & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • MNOV
  • Stock Information
  • Founded
  • VIGL 2020
  • MNOV 2000
  • Country
  • VIGL United States
  • MNOV United States
  • Employees
  • VIGL N/A
  • MNOV N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • MNOV Biotechnology: Pharmaceutical Preparations
  • Sector
  • VIGL Health Care
  • MNOV Health Care
  • Exchange
  • VIGL Nasdaq
  • MNOV Nasdaq
  • Market Cap
  • VIGL 89.3M
  • MNOV 91.7M
  • IPO Year
  • VIGL 2022
  • MNOV 2005
  • Fundamental
  • Price
  • VIGL $2.71
  • MNOV $1.87
  • Analyst Decision
  • VIGL Strong Buy
  • MNOV Strong Buy
  • Analyst Count
  • VIGL 5
  • MNOV 1
  • Target Price
  • VIGL $21.00
  • MNOV $9.00
  • AVG Volume (30 Days)
  • VIGL 2.7M
  • MNOV 17.9K
  • Earning Date
  • VIGL 03-25-2025
  • MNOV 02-18-2025
  • Dividend Yield
  • VIGL N/A
  • MNOV N/A
  • EPS Growth
  • VIGL N/A
  • MNOV N/A
  • EPS
  • VIGL N/A
  • MNOV N/A
  • Revenue
  • VIGL N/A
  • MNOV N/A
  • Revenue This Year
  • VIGL N/A
  • MNOV N/A
  • Revenue Next Year
  • VIGL N/A
  • MNOV N/A
  • P/E Ratio
  • VIGL N/A
  • MNOV N/A
  • Revenue Growth
  • VIGL N/A
  • MNOV N/A
  • 52 Week Low
  • VIGL $1.49
  • MNOV $1.12
  • 52 Week High
  • VIGL $6.06
  • MNOV $2.55
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 68.53
  • MNOV 42.84
  • Support Level
  • VIGL $2.55
  • MNOV $1.82
  • Resistance Level
  • VIGL $2.88
  • MNOV $1.97
  • Average True Range (ATR)
  • VIGL 0.23
  • MNOV 0.07
  • MACD
  • VIGL 0.04
  • MNOV -0.00
  • Stochastic Oscillator
  • VIGL 80.23
  • MNOV 20.83

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

Share on Social Networks: